Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo

Kristen L. Kozielski, Alejandro Ruiz-Valls, Stephany Y. Tzeng, Hugo Guerrero Cazares, Yuan Rui, Yuxin Li, Hannah J. Vaughan, Marissa Gionet-Gonzales, Casey Vantucci, Jayoung Kim, Paula Schiapparelli, Rawan Al-Kharboosh, Alfredo Quinones-Hinojosa, Jordan J. Green

Research output: Contribution to journalArticle

Abstract

Novel treatments for glioblastoma (GBM)are urgently needed, particularly those which can simultaneously target GBM cells’ ability to grow and migrate. Herein, we describe a synthetic, bioreducible, biodegradable polymer that can package and deliver hundreds of siRNA molecules into a single nanoparticle, facilitating combination therapy against multiple GBM-promoting targets. We demonstrate that siRNA delivery with these polymeric nanoparticles is cancer-selective, thereby avoiding potential side effects in healthy cells. We show that we can deliver siRNAs targeting several anti-GBM genes (Robo1, YAP1, NKCC1, EGFR, and survivin)simultaneously and within the same nanoparticles. Robo1 (roundabout homolog 1)siRNA delivery by biodegradable particles was found to trigger GBM cell death, as did non-viral delivery of NKCC1, EGFR, and survivin siRNA. Most importantly, combining several anti-GBM siRNAs into a nanoparticle formulation leads to high GBM cell death, reduces GBM migration in vitro, and reduces tumor burden over time following intratumoral administration. We show that certain genes, like survivin and EGFR, are important for GBM survival, while NKCC1, is more crucial for cancer cell migration. This represents a powerful platform technology with the potential to serve as a multimodal therapeutic for cancer.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalBiomaterials
Volume209
DOIs
StatePublished - Jul 1 2019

Fingerprint

Glioblastoma
Nanoparticles
Small Interfering RNA
Cell death
Neoplasms
Genes
Cells
Biodegradable polymers
Tumors
Cell Death
Molecules
In Vitro Techniques
Tumor Burden
Cell Movement
Polymers
Technology
Survival
Therapeutics

Keywords

  • Cancer therapy
  • Combination therapy
  • Gene therapy
  • Nanoparticle
  • siRNA

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo. / Kozielski, Kristen L.; Ruiz-Valls, Alejandro; Tzeng, Stephany Y.; Guerrero Cazares, Hugo; Rui, Yuan; Li, Yuxin; Vaughan, Hannah J.; Gionet-Gonzales, Marissa; Vantucci, Casey; Kim, Jayoung; Schiapparelli, Paula; Al-Kharboosh, Rawan; Quinones-Hinojosa, Alfredo; Green, Jordan J.

In: Biomaterials, Vol. 209, 01.07.2019, p. 79-87.

Research output: Contribution to journalArticle

Kozielski, KL, Ruiz-Valls, A, Tzeng, SY, Guerrero Cazares, H, Rui, Y, Li, Y, Vaughan, HJ, Gionet-Gonzales, M, Vantucci, C, Kim, J, Schiapparelli, P, Al-Kharboosh, R, Quinones-Hinojosa, A & Green, JJ 2019, 'Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo', Biomaterials, vol. 209, pp. 79-87. https://doi.org/10.1016/j.biomaterials.2019.04.020
Kozielski, Kristen L. ; Ruiz-Valls, Alejandro ; Tzeng, Stephany Y. ; Guerrero Cazares, Hugo ; Rui, Yuan ; Li, Yuxin ; Vaughan, Hannah J. ; Gionet-Gonzales, Marissa ; Vantucci, Casey ; Kim, Jayoung ; Schiapparelli, Paula ; Al-Kharboosh, Rawan ; Quinones-Hinojosa, Alfredo ; Green, Jordan J. / Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo. In: Biomaterials. 2019 ; Vol. 209. pp. 79-87.
@article{96ecc6c1f8b6420f9929dbba8fd88683,
title = "Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo",
abstract = "Novel treatments for glioblastoma (GBM)are urgently needed, particularly those which can simultaneously target GBM cells’ ability to grow and migrate. Herein, we describe a synthetic, bioreducible, biodegradable polymer that can package and deliver hundreds of siRNA molecules into a single nanoparticle, facilitating combination therapy against multiple GBM-promoting targets. We demonstrate that siRNA delivery with these polymeric nanoparticles is cancer-selective, thereby avoiding potential side effects in healthy cells. We show that we can deliver siRNAs targeting several anti-GBM genes (Robo1, YAP1, NKCC1, EGFR, and survivin)simultaneously and within the same nanoparticles. Robo1 (roundabout homolog 1)siRNA delivery by biodegradable particles was found to trigger GBM cell death, as did non-viral delivery of NKCC1, EGFR, and survivin siRNA. Most importantly, combining several anti-GBM siRNAs into a nanoparticle formulation leads to high GBM cell death, reduces GBM migration in vitro, and reduces tumor burden over time following intratumoral administration. We show that certain genes, like survivin and EGFR, are important for GBM survival, while NKCC1, is more crucial for cancer cell migration. This represents a powerful platform technology with the potential to serve as a multimodal therapeutic for cancer.",
keywords = "Cancer therapy, Combination therapy, Gene therapy, Nanoparticle, siRNA",
author = "Kozielski, {Kristen L.} and Alejandro Ruiz-Valls and Tzeng, {Stephany Y.} and {Guerrero Cazares}, Hugo and Yuan Rui and Yuxin Li and Vaughan, {Hannah J.} and Marissa Gionet-Gonzales and Casey Vantucci and Jayoung Kim and Paula Schiapparelli and Rawan Al-Kharboosh and Alfredo Quinones-Hinojosa and Green, {Jordan J.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.biomaterials.2019.04.020",
language = "English (US)",
volume = "209",
pages = "79--87",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo

AU - Kozielski, Kristen L.

AU - Ruiz-Valls, Alejandro

AU - Tzeng, Stephany Y.

AU - Guerrero Cazares, Hugo

AU - Rui, Yuan

AU - Li, Yuxin

AU - Vaughan, Hannah J.

AU - Gionet-Gonzales, Marissa

AU - Vantucci, Casey

AU - Kim, Jayoung

AU - Schiapparelli, Paula

AU - Al-Kharboosh, Rawan

AU - Quinones-Hinojosa, Alfredo

AU - Green, Jordan J.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Novel treatments for glioblastoma (GBM)are urgently needed, particularly those which can simultaneously target GBM cells’ ability to grow and migrate. Herein, we describe a synthetic, bioreducible, biodegradable polymer that can package and deliver hundreds of siRNA molecules into a single nanoparticle, facilitating combination therapy against multiple GBM-promoting targets. We demonstrate that siRNA delivery with these polymeric nanoparticles is cancer-selective, thereby avoiding potential side effects in healthy cells. We show that we can deliver siRNAs targeting several anti-GBM genes (Robo1, YAP1, NKCC1, EGFR, and survivin)simultaneously and within the same nanoparticles. Robo1 (roundabout homolog 1)siRNA delivery by biodegradable particles was found to trigger GBM cell death, as did non-viral delivery of NKCC1, EGFR, and survivin siRNA. Most importantly, combining several anti-GBM siRNAs into a nanoparticle formulation leads to high GBM cell death, reduces GBM migration in vitro, and reduces tumor burden over time following intratumoral administration. We show that certain genes, like survivin and EGFR, are important for GBM survival, while NKCC1, is more crucial for cancer cell migration. This represents a powerful platform technology with the potential to serve as a multimodal therapeutic for cancer.

AB - Novel treatments for glioblastoma (GBM)are urgently needed, particularly those which can simultaneously target GBM cells’ ability to grow and migrate. Herein, we describe a synthetic, bioreducible, biodegradable polymer that can package and deliver hundreds of siRNA molecules into a single nanoparticle, facilitating combination therapy against multiple GBM-promoting targets. We demonstrate that siRNA delivery with these polymeric nanoparticles is cancer-selective, thereby avoiding potential side effects in healthy cells. We show that we can deliver siRNAs targeting several anti-GBM genes (Robo1, YAP1, NKCC1, EGFR, and survivin)simultaneously and within the same nanoparticles. Robo1 (roundabout homolog 1)siRNA delivery by biodegradable particles was found to trigger GBM cell death, as did non-viral delivery of NKCC1, EGFR, and survivin siRNA. Most importantly, combining several anti-GBM siRNAs into a nanoparticle formulation leads to high GBM cell death, reduces GBM migration in vitro, and reduces tumor burden over time following intratumoral administration. We show that certain genes, like survivin and EGFR, are important for GBM survival, while NKCC1, is more crucial for cancer cell migration. This represents a powerful platform technology with the potential to serve as a multimodal therapeutic for cancer.

KW - Cancer therapy

KW - Combination therapy

KW - Gene therapy

KW - Nanoparticle

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=85064873316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064873316&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2019.04.020

DO - 10.1016/j.biomaterials.2019.04.020

M3 - Article

VL - 209

SP - 79

EP - 87

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -